No Added Benefit With Spartalizumab in BRAF-Mutant Melanoma

Source: Cancer Therapy Advisor, January 2022

Adding spartalizumab to treatment with dabrafenib and trametinib did not improve progression-free survival (PFS) in patients with unresectable or metastatic BRAF V600-mutant melanoma, according to a phase 3 trial published in the Journal of Clinical Oncology.1

The phase 3 COMBI-i trial (ClinicalTrials.gov Identifier: NCT02967692) was designed to investigate whether the upfront combination of a PD-1 inhibitor, MEK inhibitor, and BRAF inhibitor could yield durable responses in patients with BRAF V600-mutant unresectable or metastatic melanoma.

READ THE ORIGINAL FULL ARTICLE

 

Menu